A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment

G. Schifitto, J. Zhang, S. R. Evans, N. Sacktor, D. Simpson, L. L. Millar, V. L. Hung, E. N. Miller, E. Smith, R. J. Ellis, V. Valcour, E. Singer, C. M. Marra, D. Kolson, J. Weihe, Rory P Remmel, D. Katzenstein, D. B. Clifford, K. Nuffer, S. CahillD. Burgess, K. Carter, M. Shoemaker, A. Weisbeck, N. Hanks, M. Watters, S. A. Chafey, S. Dunaway, M. Perrin, Joseph Quinn, N. Venna, T. Flynn, T. Spitz, M. Gould, B. Cohen, L. Reisberg, R. Diaz-Arrastia, C. Lohner, K. Marder, R. Clouse, D. Mildvan, J. Bailey, K. Tashima, H. Sousa, D. Currin, S. Pedersen

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

BACKGROUND: Cognitive impairment continues to be a significant neurologic complication of HIV infection and has been associated with oxidative stress-induced neuronal injury. Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties. This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance. METHODS: HIV-1 infected individuals with impaired cognitive functioning were enrolled in this placebo-controlled, three-arm study of STS across 17 sites. Cognitive impairment was determined using a standard battery of neuropsychological tests. Subjects were randomized to receive STS 3 mg/24 hours, STS 6 mg/24 hours, or matching placebo patches daily. The primary efficacy endpoint was defined as the change in neuropsychological composite Z-score (NPZ-6) from baseline to week 24. Measures of safety included frequencies of adverse experiences and abnormal results on laboratory tests. RESULTS: A total of 128 subjects (88% men, 51% white) were enrolled, median age 45 years. Most subjects (62%) had mild to moderate AIDS dementia complex. The 24-week NPZ-6 median (interquartile range) changes were 0.22 (-0.28, 0.55) for the selegiline 3 mg/24 hours arm, 0.21 (-0.18, 0.62) for the selegiline 6 mg/24 hours arm, and 0.28 (-0.16, 0.64) for the placebo arm (a positive score indicates improvement from baseline) (p = 0.914). Severe laboratory abnormalities were few and occurred in similar proportion among the three treatment arms. CONCLUSION: Selegiline was safe and well tolerated by HIV-infected individuals with cognitive impairment and mild to moderate immune suppression; however, no cognitive or functional improvement was observed in this phase II study.

Original languageEnglish (US)
Pages (from-to)1314-1321
Number of pages8
JournalNeurology
Volume69
Issue number13
DOIs
StatePublished - Jan 1 2007

Fingerprint

Selegiline
Multicenter Studies
HIV
Placebos
AIDS Dementia Complex
Safety
Cognitive Dysfunction
Monoamine Oxidase Inhibitors
Neuropsychological Tests
Monoamine Oxidase
Nervous System
HIV Infections
HIV-1
Oxidative Stress
Antioxidants

Cite this

Schifitto, G., Zhang, J., Evans, S. R., Sacktor, N., Simpson, D., Millar, L. L., ... Pedersen, S. (2007). A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology, 69(13), 1314-1321. https://doi.org/10.1212/01.wnl.0000268487.78753.0f

A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. / Schifitto, G.; Zhang, J.; Evans, S. R.; Sacktor, N.; Simpson, D.; Millar, L. L.; Hung, V. L.; Miller, E. N.; Smith, E.; Ellis, R. J.; Valcour, V.; Singer, E.; Marra, C. M.; Kolson, D.; Weihe, J.; Remmel, Rory P; Katzenstein, D.; Clifford, D. B.; Nuffer, K.; Cahill, S.; Burgess, D.; Carter, K.; Shoemaker, M.; Weisbeck, A.; Hanks, N.; Watters, M.; Chafey, S. A.; Dunaway, S.; Perrin, M.; Quinn, Joseph; Venna, N.; Flynn, T.; Spitz, T.; Gould, M.; Cohen, B.; Reisberg, L.; Diaz-Arrastia, R.; Lohner, C.; Marder, K.; Clouse, R.; Mildvan, D.; Bailey, J.; Tashima, K.; Sousa, H.; Currin, D.; Pedersen, S.

In: Neurology, Vol. 69, No. 13, 01.01.2007, p. 1314-1321.

Research output: Contribution to journalArticle

Schifitto, G, Zhang, J, Evans, SR, Sacktor, N, Simpson, D, Millar, LL, Hung, VL, Miller, EN, Smith, E, Ellis, RJ, Valcour, V, Singer, E, Marra, CM, Kolson, D, Weihe, J, Remmel, RP, Katzenstein, D, Clifford, DB, Nuffer, K, Cahill, S, Burgess, D, Carter, K, Shoemaker, M, Weisbeck, A, Hanks, N, Watters, M, Chafey, SA, Dunaway, S, Perrin, M, Quinn, J, Venna, N, Flynn, T, Spitz, T, Gould, M, Cohen, B, Reisberg, L, Diaz-Arrastia, R, Lohner, C, Marder, K, Clouse, R, Mildvan, D, Bailey, J, Tashima, K, Sousa, H, Currin, D & Pedersen, S 2007, 'A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment', Neurology, vol. 69, no. 13, pp. 1314-1321. https://doi.org/10.1212/01.wnl.0000268487.78753.0f
Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007 Jan 1;69(13):1314-1321. https://doi.org/10.1212/01.wnl.0000268487.78753.0f
Schifitto, G. ; Zhang, J. ; Evans, S. R. ; Sacktor, N. ; Simpson, D. ; Millar, L. L. ; Hung, V. L. ; Miller, E. N. ; Smith, E. ; Ellis, R. J. ; Valcour, V. ; Singer, E. ; Marra, C. M. ; Kolson, D. ; Weihe, J. ; Remmel, Rory P ; Katzenstein, D. ; Clifford, D. B. ; Nuffer, K. ; Cahill, S. ; Burgess, D. ; Carter, K. ; Shoemaker, M. ; Weisbeck, A. ; Hanks, N. ; Watters, M. ; Chafey, S. A. ; Dunaway, S. ; Perrin, M. ; Quinn, Joseph ; Venna, N. ; Flynn, T. ; Spitz, T. ; Gould, M. ; Cohen, B. ; Reisberg, L. ; Diaz-Arrastia, R. ; Lohner, C. ; Marder, K. ; Clouse, R. ; Mildvan, D. ; Bailey, J. ; Tashima, K. ; Sousa, H. ; Currin, D. ; Pedersen, S. / A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. In: Neurology. 2007 ; Vol. 69, No. 13. pp. 1314-1321.
@article{7d46237aa37442e2a6dfeef1863f0e85,
title = "A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment",
abstract = "BACKGROUND: Cognitive impairment continues to be a significant neurologic complication of HIV infection and has been associated with oxidative stress-induced neuronal injury. Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties. This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance. METHODS: HIV-1 infected individuals with impaired cognitive functioning were enrolled in this placebo-controlled, three-arm study of STS across 17 sites. Cognitive impairment was determined using a standard battery of neuropsychological tests. Subjects were randomized to receive STS 3 mg/24 hours, STS 6 mg/24 hours, or matching placebo patches daily. The primary efficacy endpoint was defined as the change in neuropsychological composite Z-score (NPZ-6) from baseline to week 24. Measures of safety included frequencies of adverse experiences and abnormal results on laboratory tests. RESULTS: A total of 128 subjects (88{\%} men, 51{\%} white) were enrolled, median age 45 years. Most subjects (62{\%}) had mild to moderate AIDS dementia complex. The 24-week NPZ-6 median (interquartile range) changes were 0.22 (-0.28, 0.55) for the selegiline 3 mg/24 hours arm, 0.21 (-0.18, 0.62) for the selegiline 6 mg/24 hours arm, and 0.28 (-0.16, 0.64) for the placebo arm (a positive score indicates improvement from baseline) (p = 0.914). Severe laboratory abnormalities were few and occurred in similar proportion among the three treatment arms. CONCLUSION: Selegiline was safe and well tolerated by HIV-infected individuals with cognitive impairment and mild to moderate immune suppression; however, no cognitive or functional improvement was observed in this phase II study.",
author = "G. Schifitto and J. Zhang and Evans, {S. R.} and N. Sacktor and D. Simpson and Millar, {L. L.} and Hung, {V. L.} and Miller, {E. N.} and E. Smith and Ellis, {R. J.} and V. Valcour and E. Singer and Marra, {C. M.} and D. Kolson and J. Weihe and Remmel, {Rory P} and D. Katzenstein and Clifford, {D. B.} and K. Nuffer and S. Cahill and D. Burgess and K. Carter and M. Shoemaker and A. Weisbeck and N. Hanks and M. Watters and Chafey, {S. A.} and S. Dunaway and M. Perrin and Joseph Quinn and N. Venna and T. Flynn and T. Spitz and M. Gould and B. Cohen and L. Reisberg and R. Diaz-Arrastia and C. Lohner and K. Marder and R. Clouse and D. Mildvan and J. Bailey and K. Tashima and H. Sousa and D. Currin and S. Pedersen",
year = "2007",
month = "1",
day = "1",
doi = "10.1212/01.wnl.0000268487.78753.0f",
language = "English (US)",
volume = "69",
pages = "1314--1321",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment

AU - Schifitto, G.

AU - Zhang, J.

AU - Evans, S. R.

AU - Sacktor, N.

AU - Simpson, D.

AU - Millar, L. L.

AU - Hung, V. L.

AU - Miller, E. N.

AU - Smith, E.

AU - Ellis, R. J.

AU - Valcour, V.

AU - Singer, E.

AU - Marra, C. M.

AU - Kolson, D.

AU - Weihe, J.

AU - Remmel, Rory P

AU - Katzenstein, D.

AU - Clifford, D. B.

AU - Nuffer, K.

AU - Cahill, S.

AU - Burgess, D.

AU - Carter, K.

AU - Shoemaker, M.

AU - Weisbeck, A.

AU - Hanks, N.

AU - Watters, M.

AU - Chafey, S. A.

AU - Dunaway, S.

AU - Perrin, M.

AU - Quinn, Joseph

AU - Venna, N.

AU - Flynn, T.

AU - Spitz, T.

AU - Gould, M.

AU - Cohen, B.

AU - Reisberg, L.

AU - Diaz-Arrastia, R.

AU - Lohner, C.

AU - Marder, K.

AU - Clouse, R.

AU - Mildvan, D.

AU - Bailey, J.

AU - Tashima, K.

AU - Sousa, H.

AU - Currin, D.

AU - Pedersen, S.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - BACKGROUND: Cognitive impairment continues to be a significant neurologic complication of HIV infection and has been associated with oxidative stress-induced neuronal injury. Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties. This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance. METHODS: HIV-1 infected individuals with impaired cognitive functioning were enrolled in this placebo-controlled, three-arm study of STS across 17 sites. Cognitive impairment was determined using a standard battery of neuropsychological tests. Subjects were randomized to receive STS 3 mg/24 hours, STS 6 mg/24 hours, or matching placebo patches daily. The primary efficacy endpoint was defined as the change in neuropsychological composite Z-score (NPZ-6) from baseline to week 24. Measures of safety included frequencies of adverse experiences and abnormal results on laboratory tests. RESULTS: A total of 128 subjects (88% men, 51% white) were enrolled, median age 45 years. Most subjects (62%) had mild to moderate AIDS dementia complex. The 24-week NPZ-6 median (interquartile range) changes were 0.22 (-0.28, 0.55) for the selegiline 3 mg/24 hours arm, 0.21 (-0.18, 0.62) for the selegiline 6 mg/24 hours arm, and 0.28 (-0.16, 0.64) for the placebo arm (a positive score indicates improvement from baseline) (p = 0.914). Severe laboratory abnormalities were few and occurred in similar proportion among the three treatment arms. CONCLUSION: Selegiline was safe and well tolerated by HIV-infected individuals with cognitive impairment and mild to moderate immune suppression; however, no cognitive or functional improvement was observed in this phase II study.

AB - BACKGROUND: Cognitive impairment continues to be a significant neurologic complication of HIV infection and has been associated with oxidative stress-induced neuronal injury. Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties. This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance. METHODS: HIV-1 infected individuals with impaired cognitive functioning were enrolled in this placebo-controlled, three-arm study of STS across 17 sites. Cognitive impairment was determined using a standard battery of neuropsychological tests. Subjects were randomized to receive STS 3 mg/24 hours, STS 6 mg/24 hours, or matching placebo patches daily. The primary efficacy endpoint was defined as the change in neuropsychological composite Z-score (NPZ-6) from baseline to week 24. Measures of safety included frequencies of adverse experiences and abnormal results on laboratory tests. RESULTS: A total of 128 subjects (88% men, 51% white) were enrolled, median age 45 years. Most subjects (62%) had mild to moderate AIDS dementia complex. The 24-week NPZ-6 median (interquartile range) changes were 0.22 (-0.28, 0.55) for the selegiline 3 mg/24 hours arm, 0.21 (-0.18, 0.62) for the selegiline 6 mg/24 hours arm, and 0.28 (-0.16, 0.64) for the placebo arm (a positive score indicates improvement from baseline) (p = 0.914). Severe laboratory abnormalities were few and occurred in similar proportion among the three treatment arms. CONCLUSION: Selegiline was safe and well tolerated by HIV-infected individuals with cognitive impairment and mild to moderate immune suppression; however, no cognitive or functional improvement was observed in this phase II study.

UR - http://www.scopus.com/inward/record.url?scp=34748825072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748825072&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000268487.78753.0f

DO - 10.1212/01.wnl.0000268487.78753.0f

M3 - Article

C2 - 17652642

AN - SCOPUS:34748825072

VL - 69

SP - 1314

EP - 1321

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 13

ER -